Reducing Pharmaceutical Risk The major non-technical reasons for discontinuations (of drugs in development) are marketing re-assessments or management discontent. Most occur before sufficient data are available to make informed judgments….
Corporate Management The key element in developing a shared purpose is mutual trust. Without trust, people will engage in all kinds of self-centered behavior to assert their own identities and…
Organization at the Corporate Level A staff of four hundred represents the critical number in a firm taken over. It is the number which separates the personal boss from the…
Models of International Operations A method developed on one continent has difficulty being accepted on another. –Fritz Beller The term international operations is used in this chapter to describe how…
Future Environments for Drug Discovery and Development The only solid piece of scientific truth about which I feel totally confident is that we are profoundly ignorant about nature. Indeed, I…
Stimulating Innovation and Increasing Efficiency with the Right Questions, People, Milieu, and Approaches The first intimations of a new idea may be too nebulous to be captured and arranged for…
A New Paradigm of Drug Development However beautiful the strategy, you should occasionally look at the results. –Winston Churchill, British Prime Minister. This chapter presents a 25,000 foot view of…
Evaluating and Interpreting Data Men love to wonder, and that is the seed of science. –Ralph Waldo Emerson (1803-1882), American essayist and poet. From Society and Solitude (1870). He who…
Extrapolating Animal Safety and Efficacy Data to Humans Some of the drugs popular in (country X) and not elsewhere fall into the category of good ideas that lack good data…
Biotechnology It has now been more than fifteen years since Robert Swanson, a young man who understood both finance and science, invited Herbert Boyer, a shy molecular biologist at the…
